DiaMedica Therapeutics Inc. (DMAC)
DMAC Stock Price Chart
Explore DiaMedica Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze DMAC price movements and trends.
DMAC Company Profile
Discover essential business fundamentals and corporate details for DiaMedica Therapeutics Inc. (DMAC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Aug 2012
Employees
27.00
Website
https://www.diamedica.comCEO
Dietrich John Pauls MBA
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DMAC Financial Timeline
Browse a chronological timeline of DiaMedica Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.15.
Earnings released on 12 Aug 2025
EPS came in at -$0.18 matching the estimated -$0.18.
Earnings released on 13 May 2025
EPS came in at -$0.18 matching the estimated -$0.18.
Earnings released on 17 Mar 2025
EPS came in at -$0.18 falling short of the estimated -$0.17 by -5.88%.
Earnings released on 13 Nov 2024
EPS came in at -$0.15 matching the estimated -$0.15.
Earnings released on 7 Aug 2024
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%.
Earnings released on 8 May 2024
EPS came in at -$0.14 surpassing the estimated -$0.16 by +12.50%.
Earnings released on 19 Mar 2024
EPS came in at -$0.14 matching the estimated -$0.14, while revenue for the quarter reached $30.84M .
Earnings released on 13 Nov 2023
EPS came in at -$0.12 surpassing the estimated -$0.14 by +14.29%.
Earnings released on 14 Aug 2023
EPS came in at -$0.16 surpassing the estimated -$0.22 by +27.27%.
Earnings released on 15 May 2023
EPS came in at -$0.20 falling short of the estimated -$0.16 by -25.00%.
Earnings released on 28 Mar 2023
EPS came in at -$0.14 matching the estimated -$0.14.
Earnings released on 9 Nov 2022
EPS came in at -$0.12 surpassing the estimated -$0.13 by +7.69%, while revenue for the quarter reached $76.00K .
Earnings released on 10 Aug 2022
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $13.00K .
Earnings released on 4 May 2022
EPS came in at -$0.13 surpassing the estimated -$0.20 by +35.00%.
Earnings released on 14 Mar 2022
EPS came in at -$0.10 surpassing the estimated -$0.16 by +37.50%.
Earnings released on 10 Nov 2021
EPS came in at -$0.18 surpassing the estimated -$0.23 by +21.74%.
Earnings released on 11 Aug 2021
EPS came in at -$0.17 surpassing the estimated -$0.19 by +10.53%.
Earnings released on 5 May 2021
EPS came in at -$0.19 surpassing the estimated -$0.23 by +17.39%.
Earnings released on 10 Mar 2021
EPS came in at -$0.23 falling short of the estimated -$0.18 by -27.78%.
Earnings released on 4 Nov 2020
EPS came in at -$0.19 .
DMAC Stock Performance
Access detailed DMAC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.